Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments
Open accessThe DOI matches its Crossref record; 7 of the 7 references it cites were found in a registry or an index.
Abstract
INTRODUCTION: Since the cystic fibrosis (CF) gene was discovered in 1989, researchers have worked to develop a gene therapy. One of the most promising and enduring vectors is the AAV, which has been shown to be safe. In particular, several clinical trials have been conducted with AAV serotype 2. All of them detected viral genomes, but identification of mRNA transduction was not consistent; clinical outcomes in Phase II studies were also inconsistent. The lack of a positive outcome has been attributed to a less-than-efficient viral infection by AAV2, a weak transgene promoter and the host immune response to the vector. Areas covered: Herein, the authors focus on AAV gene therapy for CF, evaluating past experience with this approach and identifying ways forward, based on the progress that has already been made in identifying and overcoming the limitations of AAV gene therapy. Expert opinion: Such progress makes it clear that this is an opportune time to push forward toward the development of a gene therapy for CF. Drugs to treat the basic defect in CF represent a remarkable advance but cannot treat a significant cohort of patients with rare mutations. Thus, there is a critical need to develop a gene therapy for those individuals.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Identification of the Cystic Fibrosis Gene: Genetic Analysis
Kerem, B.-S., Rommens, J. M., Buchanan, J. A., Markiewicz, D., Cox, T. K., Chakravarti, A., Buchwald, M., & Tsui, L.-C. (1989) · Science · doi:10.1126/science.2570460 · Cited by 4,142
Immune responses to AAV vectors: overcoming barriers to successful gene therapy
Mingozzi, F., & High, K. A. (2013) · Blood · doi:10.1182/blood-2013-01-306647 · Cited by 955 · cited 3×
“many people who have already been exposed to AAV [29].”
BackgroundInfluentialHogan, B. L. M., Barkauskas, C. E., Chapman, H. A., Epstein, J. A., Jain, R., Hsia, C. C. W., Niklason, L., Calle, E., Le, A., Randell, S. H., et al. (2014) · Cell Stem Cell · doi:10.1016/j.stem.2014.07.012 · Cited by 876 · cited 1×
“The airway surface cells which possess functional CFTR have a finite life span [60].”
BackgroundSosnay, P. R., Siklosi, K. R., Van Goor, F., Kaniecki, K., Yu, H., Sharma, N., Ramalho, A. S., Amaral, M. D., Dorfman, R., Zielenski, J., et al. (2013) · Nature Genetics · doi:10.1038/ng.2745 · Cited by 630
Duan, D., Sharma, P., Yang, J., Yue, Y., Dudus, L., Zhang, Y., Fisher, K. J., & Engelhardt, J. F. (1998) · Journal of Virology · doi:10.1128/jvi.72.11.8568-8577.1998 · Cited by 522 · cited 1×
“Studies that have examined the fate of rep-deleted vector DNA have indicated that the ITR– CFTR–ITR coding sequence is located episomally or integrated randomly at a low frequency in the host cells [25], leading to long-term expression of the recombinant protein in the infected cells.”
BackgroundEndosomal processing limits gene transfer to polarized airway epithelia by adeno-associated virus
Duan, D., Yue, Y., Yan, Z., Yang, J., & Engelhardt, J. F. (2000) · Journal of Clinical Investigation · doi:10.1172/jci8317 · Cited by 391 · cited 1×
“The AAV2 virus that does manage to enter the cell from the apical membrane does so via a different mechanism of endocytosis, in which the viral particles are ubiquitinated and ultimately degraded in the proteasome, and therefore they do not reach the nucleus, where transduction normally occurs [42].”
BackgroundSynthetic Intron Improves Transduction Efficiency of Trans -Splicing Adeno-Associated Viral Vectors
Lai, Y., Yue, Y., Liu, M., & Duan, D. (2006) · Human Gene Therapy · doi:10.1089/hum.2006.17.1036 · Cited by 37 · cited 1×
“and collaborators [58] achieved widespread expression of a 6-kb ΔH2-R19 mini-dystrophin gene in skeletal muscle using AAV to rescue the dystrophic phenotype in mdx mouse model”
Method
Cited by
Lipid Nanoparticle-Delivered Chemically Modified mRNA Restores Chloride Secretion in Cystic Fibrosis
Robinson, E., MacDonald, K. D., Slaughter, K., McKinney, M., Patel, S., Sun, C., & Sahay, G. (2018) · Molecular Therapy · doi:10.1016/j.ymthe.2018.05.014 · Cited by 272
Can Adeno-Associated Viral Vectors Deliver Effectively Large Genes?
Tornabene, P., & Trapani, I. (2020) · Human Gene Therapy · doi:10.1089/hum.2019.220 · Cited by 76
Feasibility of using NF1-GRD and AAV for gene replacement therapy in NF1-associated tumors
Bai, R.-Y., Esposito, D., Tam, A. J., McCormick, F., Riggins, G. J., Wade Clapp, D., & Staedtke, V. (2019) · Gene Therapy · doi:10.1038/s41434-019-0080-9 · Cited by 38
Translational research to enable personalized treatment of cystic fibrosis
Hagemeijer, M. C., Siegwart, D. J., Strug, L. J., Cebotaru, L., Torres, M. J., Sofoluwe, A., & Beekman, J. M. (2018) · Journal of Cystic Fibrosis · doi:10.1016/j.jcf.2017.10.017 · Cited by 22
Self-citation(2019) · Cellular Physiology and Biochemistry · doi:10.33594/000000089 · Cited by 5
Self-citation
Metadata
- Authors
- Guggino, W. B., & Cebotaru, L.
- Venue
- Expert Opinion on Biological Therapy
- Publisher
- Informa UK Limited
- Published
- 2017-07-06
- Volume
- 17
- Issue
- 10
- Pages
- 1265-1273
- ISSN
- 1471-2598 (ISSN-L)
- 1744-7682
- OpenAlex
- W2732202264
- Cited by
- 63
- References
- 7
- FWCI
- 4.09
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. https://app.cochat.ai/papers/10.1080/14712598.2017.1347630
- The paper
- Guggino, W. B., & Cebotaru, L. (2017). Adeno-Associated Virus (AAV) gene therapy for cystic fibrosis: current barriers and recent developments. Expert Opinion on Biological Therapy. https://doi.org/10.1080/14712598.2017.1347630
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.